BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ben MD, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(26): 8341-8350 [PMID: 25024593 DOI: 10.3748/wjg.v20.i26.8341] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Spahis S, Alvarez F, Ahmed N, Dubois J, Jalbout R, Paganelli M, Grzywacz K, Delvin E, Peretti N, Levy E. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. The Journal of Nutritional Biochemistry 2018;58:28-36. [DOI: 10.1016/j.jnutbio.2018.03.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
2 Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019;37:65-72. [PMID: 30705499 DOI: 10.2337/cd18-0026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
3 Marinho PC, Vieira AB, Pereira PG, Rabelo K, Ciambarella BT, Nascimento ALR, Cortez E, Moura AS, Guimarães FV, Martins MA, Barquero G, Ferreira RN, de Carvalho JJ. Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2018;2018:4956079. [PMID: 29853957 DOI: 10.1155/2018/4956079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Chen HJ, Liu J. Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant. Biomed Pharmacother 2018;97:1386-96. [PMID: 29156528 DOI: 10.1016/j.biopha.2017.09.093] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
5 Hariri M, Zohdi S. Effect of Vitamin D on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Clinical Trials. Int J Prev Med 2019;10:14. [PMID: 30774848 DOI: 10.4103/ijpvm.IJPVM_499_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Cho YK, Kang YM, Yoo JH, Lee J, Lee SE, Yang DH, Kang JW, Park JY, Jung CH, Kim HK, Lee WJ. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. Sci Rep 2018;8:12004. [PMID: 30104707 DOI: 10.1038/s41598-018-30465-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
7 Song BJ, Akbar M, Jo I, Hardwick JP, Abdelmegeed MA. Translational Implications of the Alcohol-Metabolizing Enzymes, Including Cytochrome P450-2E1, in Alcoholic and Nonalcoholic Liver Disease. Adv Pharmacol 2015;74:303-72. [PMID: 26233911 DOI: 10.1016/bs.apha.2015.04.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
8 Patel V, Joharapurkar A, Kshirsagar S, Patel M, Sutariya B, Patel H, Pandey D, Patel D, Ranvir R, Kadam S, Bahekar R, Jain M. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2018;96:587-596. [PMID: 29406832 DOI: 10.1139/cjpp-2017-0683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mohammadi M, Abbasalipourkabir R, Ziamajidi N. Fish oil and chicoric acid combination protects better against palmitate-induced lipid accumulation via regulating AMPK-mediated SREBP-1/FAS and PPARα/UCP2 pathways. Arch Physiol Biochem 2020;:1-9. [PMID: 32654534 DOI: 10.1080/13813455.2020.1789881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen Y, Huang H, Xu C, Yu C, Li Y. Long Non-Coding RNA Profiling in a Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight into Pathogenesis. Int J Mol Sci 2017;18:E21. [PMID: 28275212 DOI: 10.3390/ijms18010021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
11 Baratta F, Pastori D, Del Ben M, Polimeni L, Labbadia G, Di Santo S, Piemonte F, Tozzi G, Violi F, Angelico F. Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. EBioMedicine. 2015;2:750-754. [PMID: 26288848 DOI: 10.1016/j.ebiom.2015.05.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
12 Mansour-Ghanaei F, Pourmasoumi M, Hadi A, Ramezani-Jolfaie N, Joukar F. The Efficacy of Vitamin D Supplementation against Nonalcoholic Fatty Liver Disease: A Meta-Analysis. J Diet Suppl 2020;17:467-85. [PMID: 31256692 DOI: 10.1080/19390211.2019.1624671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Pani A, Giossi R, Menichelli D, Fittipaldo VA, Agnelli F, Inglese E, Romandini A, Roncato R, Pintaudi B, Del Sole F, Scaglione F. Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. Nutrients 2020;12:E3379. [PMID: 33153126 DOI: 10.3390/nu12113379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
14 Lee E, Lim Y, Kwon SW, Kwon O. Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. The Journal of Nutritional Biochemistry 2019;68:33-41. [DOI: 10.1016/j.jnutbio.2019.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
15 Wang XY, Song XL, Zhang Y, Luo G, Tai HC, Lin ZH, Zhu PL, Sun N, Chu ZS, Yu ZL, Pan SY, Tang JF, Ko KM. Evaluation of Beneficial and Adverse Effects of a Diet Supplemented with Schisandrae Fructus Seed Ethanol Extract on Lipid and Glucose Metabolism in Normal and Hypercholesterolemic/Hyperglycemic Mice. Evid Based Complement Alternat Med 2021;2021:8858962. [PMID: 33688367 DOI: 10.1155/2021/8858962] [Reference Citation Analysis]
16 Baratta F, Pastori D, Ferro D, Carluccio G, Tozzi G, Angelico F, Violi F, Del Ben M. Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease? World J Gastroenterol 2019; 25(30): 4172-4180 [PMID: 31435171 DOI: 10.3748/wjg.v25.i30.4172] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
17 Jarhahzadeh M, Alavinejad P, Farsi F, Husain D, Rezazadeh A. The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: a randomized double blind clinical trial. Diabetol Metab Syndr 2021;13:112. [PMID: 34663438 DOI: 10.1186/s13098-021-00731-7] [Reference Citation Analysis]
18 Shen X, Guo H, Xu J, Wang J. Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease. J Cell Physiol 2019;234:18169-79. [PMID: 30908654 DOI: 10.1002/jcp.28450] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
19 Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther 2015;9:4835-45. [PMID: 26316717 DOI: 10.2147/DDDT.S64877] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
20 Fujii Y, Kawamura N, Zaitsu M, Watanabe M, Goto R, Kamiyama T, Taketomi A, Shimamura T. Outcome of Living-Donor Liver Transplantation Using Grafts from Donors Treated for Fatty Liver. Ann Transplant. 2020;25:e920677. [PMID: 31919339 DOI: 10.12659/aot.920677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. BMC Med. 2016;14:92. [PMID: 27353492 DOI: 10.1186/s12916-016-0638-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 12.7] [Reference Citation Analysis]
22 Bito T, Okumura E, Fujishima M, Watanabe F. Potential of Chlorella as a Dietary Supplement to Promote Human Health. Nutrients 2020;12:E2524. [PMID: 32825362 DOI: 10.3390/nu12092524] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
23 Li Y, Chen X, Xue J, Liu J, Chen X, Wulasihan M. Flavonoids furom Coreopsis tinctoria adjust lipid metabolism in hyperlipidemia animals by down-regulating adipose differentiation-related protein. Lipids Health Dis 2014;13:193. [PMID: 25512113 DOI: 10.1186/1476-511X-13-193] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De Lorenzo A. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(17): 3150-3162 [PMID: 28533672 DOI: 10.3748/wjg.v23.i17.3150] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
25 Loffredo L, Del Ben M, Perri L, Carnevale R, Nocella C, Catasca E, Baratta F, Ceci F, Polimeni L, Gozzo P, Violi F, Angelico F. Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;44:279-86. [PMID: 27265388 DOI: 10.1111/apt.13687] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
26 Corona-Pérez A, Díaz-Muñoz M, Rodríguez IS, Cuevas E, Martínez-Gómez M, Castelán F, Rodríguez-Antolín J, Nicolás-Toledo L. High Sucrose Intake Ameliorates the Accumulation of Hepatic Triacylglycerol Promoted by Restraint Stress in Young Rats. Lipids 2015;50:1103-13. [PMID: 26399510 DOI: 10.1007/s11745-015-4066-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
27 Ebrahimi-mameghani M, Sadeghi Z, Abbasalizad Farhangi M, Vaghef-mehrabany E, Aliashrafi S. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris : A double-blind placebo-controlled randomized clinical trial. Clinical Nutrition 2017;36:1001-6. [DOI: 10.1016/j.clnu.2016.07.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
28 Noel OF, Still CD, Gerhard GS. Genetics of Bariatric Surgery Outcomes. Endocrinology and Metabolism Clinics of North America 2016;45:623-32. [DOI: 10.1016/j.ecl.2016.04.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Shen T, Xu B, Lei T, Chen L, Zhang C, Ni Z. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Exp Ther Med 2018;16:3121-8. [PMID: 30214535 DOI: 10.3892/etm.2018.6554] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
30 Loffredo L, Baratta F, Ludovica P, Battaglia S, Carnevale R, Nocella C, Novo M, Pannitteri G, Ceci F, Angelico F, Violi F, Del Ben M. Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis. Nutr Metab Cardiovasc Dis 2017;28:143-9. [PMID: 29329924 DOI: 10.1016/j.numecd.2017.10.027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
31 Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-pollack R, Plodkowski R. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines Formedical Care of Patients with Obesity. Endocrine Practice 2016;22:1-203. [DOI: 10.4158/ep161365.gl] [Cited by in Crossref: 406] [Cited by in F6Publishing: 172] [Article Influence: 67.7] [Reference Citation Analysis]
32 Knebel B, Hartwig S, Haas J, Lehr S, Goeddeke S, Susanto F, Bohne L, Jacob S, Koellmer C, Nitzgen U, Müller-Wieland D, Kotzka J. Peroxisomes compensate hepatic lipid overflow in mice with fatty liver. Biochim Biophys Acta 2015;1851:965-76. [PMID: 25790917 DOI: 10.1016/j.bbalip.2015.03.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
33 Kořínková L, Pražienková V, Černá L, Karnošová A, Železná B, Kuneš J, Maletínská L. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. Front Endocrinol (Lausanne) 2020;11:597583. [PMID: 33324348 DOI: 10.3389/fendo.2020.597583] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
34 Luo HQ, Shen J, Chen CP, Ma X, Lin C, Ouyang Q, Xuan CX, Liu J, Sun HB, Liu J. Lipid-lowering effects of oleanolic acid in hyperlipidemic patients. Chin J Nat Med. 2018;16:339-346. [PMID: 29860994 DOI: 10.1016/s1875-5364(18)30065-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Wang J, Chen Y, Pan R, Wu C, Chen S, Li L, Li Y, Yu C, Meng ZX, Xu C. Leukocyte cell-derived chemotaxin 2 promotes the development of nonalcoholic fatty liver disease through STAT-1 pathway in mice. Liver Int 2021;41:777-87. [PMID: 33555112 DOI: 10.1111/liv.14816] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Sigler MA, Congdon L, Edwards KL. An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. Clin Med Insights Gastroenterol 2018;11:1179552218787502. [PMID: 30013416 DOI: 10.1177/1179552218787502] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
37 Zhu S, Shi J, Ji C, Yang G, Xing J, Zhu F, Lin L, Xing A, Huang Z, Zhu C, Wei X, Zhang S, Gu J, Wu S. Association of the ideal cardiovascular behaviors and factors with the incidence of nonalcoholic fatty liver disease: a prospective study. European Journal of Gastroenterology & Hepatology 2018;30:578-82. [DOI: 10.1097/meg.0000000000001069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Chen Y, Chen X, Gao J, Xu C, Xu P, Li Y, Zhu Y, Yu C. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl‐Sirt1 pathway. FASEB j 2019;33:11411-9. [DOI: 10.1096/fj.201900643rrr] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
39 Khan S, Ali A, Khan S, Bakillah A, Damanhouri G, Khan A, Makki A, AlAnsari I, Banu N. Current therapies in alleviating liver disorders and cancers with a special focus on the potential of vitamin D. Nutr Metab (Lond) 2018;15:13. [PMID: 29449867 DOI: 10.1186/s12986-018-0251-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Martins E, Oliveira A. NAFLD and cardiovascular disease. Porto Biomed J 2018;3:e2. [PMID: 31595238 DOI: 10.1016/j.pbj.0000000000000002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, Jalali M, Shabani-Borujeni M, Modaresi S, Gholamalizadeh M, Doaei S. The Effects of Vitamin D Supplementation on Anthropometric and Biochemical Indices in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Front Pharmacol 2021;12:732496. [PMID: 34803681 DOI: 10.3389/fphar.2021.732496] [Reference Citation Analysis]
42 Wang ST, Zheng J, Peng HW, Cai XL, Pan XT, Li HQ, Hong QZ, Peng XE. Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2020;20:66. [PMID: 32164541 DOI: 10.1186/s12876-020-01204-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
43 Baratta F, Pastori D, Polimeni L, Tozzi G, Violi F, Angelico F, Del Ben M. Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease? Int J Mol Sci. 2015;16:28014-28021. [PMID: 26602919 DOI: 10.3390/ijms161226085] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
44 Mahady SE, George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 2016;65:1172-82. [DOI: 10.1016/j.metabol.2015.10.032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
45 Chen T, Zuo X, Wang S, Yu P, Yuan J, Wei S, Chen J, Sun Y, Gao Y, Li X. The effect of vitamin D supplementation on the progression of fibrosis in patients with chronic liver disease: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20296. [PMID: 32384521 DOI: 10.1097/MD.0000000000020296] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Del Ben M, Polimeni L, Baratta F, Pastori D, Angelico F. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol. 2017;83:88-95. [PMID: 26852185 DOI: 10.1111/bcp.12899] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
47 Silva Figueiredo P, Carla Inada A, Marcelino G, Maiara Lopes Cardozo C, de Cássia Freitas K, de Cássia Avellaneda Guimarães R, Pereira de Castro A, Aragão do Nascimento V, Aiko Hiane P. Fatty Acids Consumption: The Role Metabolic Aspects Involved in Obesity and Its Associated Disorders. Nutrients 2017;9:E1158. [PMID: 29065507 DOI: 10.3390/nu9101158] [Cited by in Crossref: 88] [Cited by in F6Publishing: 66] [Article Influence: 17.6] [Reference Citation Analysis]
48 Yu L, Yuan M, Wang L. The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: A systematic review and meta-analysis of RCTs. Pak J Med Sci 2017;33:1022-8. [PMID: 29067086 DOI: 10.12669/pjms.334.12315] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]